Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.74 |
| ▸ | THRB | P10828 | 8/20 | 0.74 |
| ▸ | BLM | P54132 | 7/20 | 0.74 |
| ▸ | RECQL | P46063 | 6/20 | 0.74 |
| ▸ | TOP2A | P11388 | 5/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.74 |
| ▸ | HTT | P42858 | 4/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.74 |
| ▸ | FYN | P06241 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leurubicin SCHEMBL29412217 | 1.00 | MEN1 (0.74) | MEN1KMT2ATHRBBLMRECQL | |
| Leurubicin SCHEMBL1231191 | 1.00 | MEN1 (0.74) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL1792990 | 0.94 | MEN1 (0.72) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL9174521 | 0.94 | MEN1 (0.78) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL9175600 | 0.94 | MEN1 (0.78) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL1795063 | 0.93 | MEN1 (0.73) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL9173911 | 0.93 | MEN1 (0.76) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL6130215 | 0.92 | MEN1 (0.73) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL16137956 | 0.92 | MEN1 (0.72) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL9172273 | 0.91 | MEN1 (0.72) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | DIATOS S.A. (FR) | 2006-12-14 | — | — | US | claimed |
| US-5962216-A | MARKER OR ANTICARCINOGENIC/ANTIINFLAMMATORY/ANTITUMOR AGENT LINKED BY CLEAVABLE SEQUENCE TO STABILIZER OF BETA-ALANINE OR SUCCINIC ACID; TARGETED DELIVERY TO CELL, CLEAVAGE BY CELL SPECIFIC FACTOR FOR ENTRY INTO CELL OR EXPRESSION OF MARKER | LA REGION WALLONNE (BE) | 1999-10-05 | — | — | US | claimed |
| CN-104174071-A | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIODEVICE INTERNAT GMBH | 2014-12-03 | — | — | CN | disclosed |
| US-8034787-B2 | Enzyme-cleavable prodrug compounds | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-7951772-B2 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2011-05-31 | — | — | US | disclosed |
| EP-1144011-B1 | PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COULTER PHARM INC (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090137494-A1 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090110753-A1 | Enzyme-cleavable prodrug compounds | MEDAREX, INC. (US) | 2009-04-30 | — | — | US | disclosed |
| WO-2008120098-A2 | PEPTIDE PRODRUGS | DIATOS (FR) | 2008-10-09 | — | — | WO | disclosed |
| US-7425541-B2 | Enzyme-cleavable prodrug compounds | MEDAREX, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-7390629-B2 | Tumor-activated prodrug compounds and treatment | LA REGION WALLONNE (BE) | 2008-06-24 | — | — | US | disclosed |
| WO-2001091798-A2 | TUMOR ACTIVATED PRODRUG COMPOUNDS | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001090139-A2 | A LIGAND FOR ENHANCING ORAL AND CNS DELIVERY OF BIOLOGICAL AGENTS | SUPRATEK PHARMA INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| EP-1144011-A2 | PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | Coulter Pharmaceutical, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001057067-A1 | LIGAND FOR VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR | SUPRATEK PHARMA INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6265540-B1 | PEPTIDE HAVING SPECIFIC AMINO ACID SEQUENCE WHICH IS CLEAVAGE SITE FOR PROSTATE SPECIFIC ANTIGEN PROTEOLYTIC ACTIVITY; ANTIPROLIFERATIVE AGENTS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2001-07-24 | — | — | US | disclosed |
| WO-2000033888-A9 | PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COULTER PHARM INC (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000033888-A2 | PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COULTER PHARMACEUTICAL, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5962216-A | MARKER OR ANTICARCINOGENIC/ANTIINFLAMMATORY/ANTITUMOR AGENT LINKED BY CLEAVABLE SEQUENCE TO STABILIZER OF BETA-ALANINE OR SUCCINIC ACID; TARGETED DELIVERY TO CELL, CLEAVAGE BY CELL SPECIFIC FACTOR FOR ENTRY INTO CELL OR EXPRESSION OF MARKER | LA REGION WALLONNE (BE) | 1999-10-05 | — | — | US | disclosed |
| EP-0294294-B1 | Amine derivatives of anthracycline antibiotics | CYTOGEN CORP (US) | 1995-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137494-A1 | Tumor-activated prodrug compounds and treatment | GZMB, B2M, TNFSF10 | MEN1 1615/4885KMT2A 2210/4885THRB 1596/4885 |
| US-20060281897-A1 | Potentialization of the activation of high molecular weight prodrugs | CD44, MMP12, FOLH1 | MEN1 1826/4885KMT2A 3864/4885THRB 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.